Menu

Top Stories

Published on Thursday, April 11, 2019

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by Susan Dentzer, visiting fellow at the Robert J. Margolis Center for Health Policy, Duke University, in Washington DC.

Photo: Francis Collins, MD, PhD, director of the NIH (left) and author Alejandro Hernandez, editorial manager of the Alpha-1 Foundation (right)

For 60 minutes, Collins, Dolsten, and Dentzer engaged in a conversation with the theme of: “Advancing the innovation ecosystem: working together for patients,” where they emphasized the need for continued collaboration between the private and public sectors, along with the patient community, in order to advance new and emerging technologies and innovative approaches for potentially life-saving treatments and new outcomes in medicine.

“We are currently living in remarkable times with amazing things happening in areas such as cancer immuno-therapy, gene therapy, and gene editing. The things that are happening right now, I had no idea they would even be possible just five or six years ago,” expressed Collins when asked about the current position “the ecosystem,” as they described the collaboration between the private and public sectors with small biotech companies; an ecosystem with symbiotic characteristics where all contributors play an important role in a tremendous team effort, in medical research.

Collins and Dolsten agreed on the importance of advocacy groups and organizations as well as the patient community, in being part of the process for better outcomes and the ability to bring new and potential treatments for various conditions to the clinic, including rare diseases, such as Alpha-1 Antitrypsin Deficiency (Alpha-1). 

“We need you, the patient community, you are the reason we have gotten this far,” said Collins.

“One of the most important resources needed for this ecosystem to strive is you, the patient. We need to line-up our resources and keep the ecosystem going, including the patient community. There is no one better to bring together what others (physicians) can do than patients: you inspire all of us,” expressed Dolsten.

The Alpha-1 Foundation applauds and supports these types of initiatives, in which patients become partners and are of vital importance for therapeutic development. 

The panel also mentioned that it is critical to spread awareness and education in the medical community, and being able to have early diagnosis and detection, while mentioning the Accelerating Medicines Partnership (AMP), a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical, and life science companies, as well as non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.

The ultimate goal of AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

“Patient participation is critical for AMP, especially to remind us what we are doing and why-and-who we are doing it for,” said Collins, who also mentioned the Foundation for the National Institutes of Health (FNIH) as being instrumental in bringing together funds and resources from both the private and public sectors, to work in mutual collaboration in research projects that will ultimately benefit the patient community.

The Alpha-1 Foundation applauds these types of initiatives that support research and bring innovative approaches to the table for the benefit of the patient community, as we are committed to finding a cure for Alpha-1 and improving the lives of Alphas, and those affected by the condition, worldwide.

For more information, please visit the Collaboration Ecosystem website and the AMP website.


Print

FDA acts to address youth e-cigarette use

Friday, September 14, 2018
The U.S. Food and Drug Administration (FDA) announced a series of critical actions related to the sale and marketing of electronic cigarettes (e-cigarettes) and related products to minors. Since March, FDA compliance checks have uncovered more...
Divider

Emergency preparation and lung disease

Wednesday, September 12, 2018
Everyone, especially patients that require the use of oxygen or other special medical equipment, should never wait long before putting an emergency plan into practice, for emergencies, catastrophes or natural or man-made disasters. And putting...
Divider

Augmentation therapy patient-pioneer, Gerry Treichel, passes away

Wednesday, September 12, 2018
It is with a heavy heart that the Alpha-1 Foundation announces the passing of Gerald (Gerry) Treichel, beloved member of the Alpha-1 community for many years and one of the pioneer patients for augmentation therapy, in the evening of Sunday,...
Divider

A good age: Denied a lung transplant, she keeps on trekking

Tuesday, September 11, 2018
In her determination, Alyce Yout has a compelling courage and buoyancy. After living with lung disease for 26 years, the former pediatric nurse had high hopes for a lung transplant last fall. “We began the journey to a transplant after...
Divider

Sharp drop in portable oxygen access blamed on provider pay changes

Monday, September 10, 2018
A coalition of pulmonary health groups called on the Centers for Medicare & Medicaid Services (CMS) to change its supplemental oxygen reimbursement policy to remove liquid oxygen from competitive bidding requirements. The American Lung...
Divider

New advances in gene therapies for rare diseases

Friday, August 31, 2018
The U.S. Food and Drug Administration (FDA) recently approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This...
Divider

Alpha-1 Foundation leadership transition

Wednesday, August 22, 2018
The Alpha-1 Foundation Board of Directors is pleased to announce that Miriam O’Day has been named as interim CEO of the Alpha-1 Foundation. Ms. O’Day has served the Foundation with distinction for nearly twenty years. The Board is...
Divider

Alpha-1 Foundation earns 8th consecutive 4-star rating from Charity Navigator

Wednesday, August 22, 2018
The Alpha-1 Foundation has earned its eighth consecutive 4-star rating from Charity Navigator, an accomplishment that only select charities achieve in the U.S. The Foundation earned its top score based on Charity Navigator’s evaluation of...
Divider

Orphan Drug Designation granted to Bronchiolitis Obliterans treatment

Friday, August 17, 2018
Onspira Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its investigational product, OSP-101, for the treatment of Bronchiolitis Obliterans (BO). BO is a progressive inflammatory condition...
Divider

Family of liver donor meets transplant recipient

Friday, August 10, 2018
On June 19, Cletus Schnieders was eating dinner with his wife Carrie and their three children (sons Trenton, 9, and Cletie, 4, and daughter Samantha, 2) in their Cincinnati home when he started to choke. Photo: Facebook/Carrie...
Divider

Living donor saved her own son’s life

Tuesday, July 31, 2018
Dara Kass is an emergency physician in New York, but she did not need to be a doctor to know that something was going on with the third child, Sammy. At birth, the baby was smaller than his two siblings. He barely grew and was lethargic; his skin...
Divider

The Assistance Fund opens new program for Alphas

Monday, July 30, 2018
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new program for individuals with Alpha-1 Antitrypsin Deficiency...
Divider
First234567891011Last

Article Search

Enter keywords in text box and click Search button for results.

Archive